Summary
PHARMATEL is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.1m and a net result of €429,692. Equity is shrinking by about 4.1% per year across the filed financial years. Its solvency ranks better than 62% of 9,723 sector peers (NACE 64, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
11-05
Gazette deed
Capital & sharesCapital decrease · Amendment of the articles · Power of attorney4 facts ▸
- General meeting, “buitengewone algemene vergadering van de aandeelhouders” (deed in Dutch)
- Capital decrease, €898,500
- Amendment of the articles, 5
- Power of attorney, TLN
24-02
Gazette deed
Reappointments: Christiaens Harry, Van Vooren Lieven and Yacelo NVPermanent representative: Tielen Ludo7 facts ▸
- General meeting, 12-09-2025
- Director reappointment, Christiaens Harry (director)
- Director reappointment, Van Vooren Lieven (director)
- Director reappointment, Yacelo NV (director)
- Permanent representative, Tielen Ludo
- Board meeting, “éénparigheid van stemmen, Raad van Bestuur” (deed in Dutch)
- Director reappointment, Yacelo NV (managing director)
About the unread acts
Of the 6 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.